Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib

Keith T. Flaherty, M.D. Of Array BioPharma Discusses Updated Data From Phase 3 COLUMBUS Trial: Encorafenib Was The Agent Of Interest In This Study, Encorafenib Was Superior To Vemurafenib.<br /><br /><br /><br />BACK... Author: Annual-Meeting Added: 06/07/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts